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Abstract 
 
The Nuclear Factor-kappaB (NF-κB) family of transcription factors is intimately 
involved in the regulation of the inflammatory responses that play a fundamental role in 
the damage of articular tissues. Thus, many studies have examined the important 
contributions of components of the NF-κB signaling pathways to the pathogenesis of 
various rheumatic diseases, and their pharmacologic modulation. Currently available 
therapeutic agents including non-steroidal antiinflammatory drugs, corticosteroids, 
nutraceuticals and disease-modifying anti-rheumatic drugs, as well as novel specific 
small molecule inhibitors have been employed.  In addition, promising strategies such as 
improved antisense DNA therapy and RNA interference have shown encouraging results. 
However, further research will be needed before NF-κB-aimed strategies become an 
effective therapy for inflammatory arthritis.  
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Introduction  
In the last few years, novel molecular approaches have provided invaluable insights 
into the multitude of complex anabolic and catabolic signals that act upon diverse cells 
from articular tissues. Many of these important processes play a key role in the 
pathogenesis of inflammation and tissue destruction, crucial components of numerous 
articular diseases (1,2). The precise interplay of these signaling pathways is essential for 
the activation of the cellular gene expression machinery. A large number of transcription 
factor families have been implicated as critical regulators of gene expression in the 
setting of the inflammatory process (3). This review focuses on the nuclear factor κB 
(NF-κB) signaling pathways, emphasizing their role in inflammation and damage to 
articular tissues, their modulation with therapeutic agents currently in use, and potential 
future strategies. 
 
NF-κB 
The NF-κB proteins are a family of ubiquitously expressed transcription factors 
that play an essential role in most immune and inflammatory responses. These 
transcription factors also have an important role in the protection of cells from apoptosis 
and in the process of intercellular signaling during normal vertebrate development. NF-
κB was first described as a B cell-specific transcription factor but has been subsequently 
shown to exist in all mammalian cell types. 
In mammals, the NF-κB family consists of five members: RelA (p65), RelB, c-
Rel, NF-κB1 (p50 and its precursor p105), and NF-κB2 (p52 and its precursor p100). 
They share a 300-amino acid domain that is designated the Rel homology domain (RHD) 
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which mediates their dimerization, interaction with the inhibitory κB (IκB) proteins, 
DNA binding and nuclear translocation. RelA (p65), RelB, and c-Rel contain a C-
terminal transcriptional activation domain (TAD) that positively regulates gene 
expression.  In contrast, p50 and p52 lack TADs, therefore, they may repress 
transcription unless bound to other NF-κB family member containing a TAD or to other 
proteins capable of recruiting coactivators (4-8). Although the NF-κB family members 
form a variety of homodimers and heterodimers,, the most prevalent activated form is the 
heterodimer RelA (p65) and p50.  Each dimmer activates its own characteristic set of 
genes and different dimers can bind to the same or distinct sites in NF-κB-dependent 
gene promoters regulating the transcription of their corresponding response genes in a 
cell-type and stimulus-type manner (9-10). 
 
NF-κB function and regulation  
 NF-κB is present in the cytoplasm of all mammalian cells in an inactive form 
associated with the IκB proteins, which include IκBα, IκBβ, IκBε,IκBγ, Bcl-3,  and the 
precursor proteins p100 and p105 (4-6). The IκB proteins typically contain C-terminal 
ankyrin repeats that are crucial for their interaction with the NF-κB proteins, and an N-
terminal leucin-rich nuclear export-sequence, that is important for the shuttling of IκBs 
between the cytoplasm and nucleus. The shuttling of IκBs is an important mechanism to 
retain the IκB-NF-κB complex in the cytoplasm of unstimulated cells. The IκB proteins 
can also act as NF-κB cofactors that ultimately either inhibit or enhance NF-κB binding 
to DNA. Thus, IκBs have both cytoplasmic and nuclear roles in regulating NF-κB 
pathways (4,6,8,11). 
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 The phosphorylation of IκBs is performed by the specific serine/threonine kinase 
IκB kinase (IKK). The IKK complex consists of at least three subunits, including the 
kinases IKKα and IKKβ (also called IKK-1 and IKK-2, respectively) and the associated 
regulatory subunit IKK-γ/NEMO (NF-κB essential modulator). IKKβ is the dominant 
kinase in the canonical patwhay of NF-κB activation, whereas IKKα appears to also play 
a significant role. Thus, a new IKKα function has been recently described; the regulation 
of histone function which in turn causes the activation of the NF-κB cannonical pathway. 
Conversely, IKKα has a unique role in the activation of the non canonical pathway. IKK-
γ/NEMO has no known kinase activity, however, is crucial for IKK complex activation 
(8,12-15). 
 A broad range of stimuli including the cytokines TNF-α and IL-1β, chemokines, 
bacterial and viral products, and free radicals activate the NF-κB dimers by triggering the 
canonical signaling pathway that leads to the IKKβ phosphorylation-induced degradation 
of IκBs (IκBα, IκBβ and IκBγ), followed by its ubiquitination by the E3 ubiquitin ligase 
complex (SCFβTrCP), and its consequent degradation by the 26S proteasome. The 
mechanism through which cytokines activate the IKK complex is not fully known. At 
least two hypotheses have been postulated: one proposes that the activation of TAK1 
(TGF-β-activated kinase-1) or MAP kinase kinase ERK1 (MEKK1) enhaces IKK 
activity, whereas the second suggests that the linkage of IKK to the receptors localized in 
the cell membrane originates its autophosphorylation and further activation. Upon 
stimulation, interaction of NEMO with receptor-interacting protein (RIP) family 
members and TNF Receptor Associated Factor (TRAF) proteins in an ubiquitin-
dependent manner would occur in either case. Although phosphorylation of IKKβ is a 
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key event in the canonical pathway, the ubiquitination and subsequent degradation of the 
multiple factors involved on its regulation are also crucial mechanisms required for NF-
κB activation (8,11,13). 
 The degradation of IκB exposes a nuclear localization signal on the NF-κB 
proteins, which then become able to translocate into the nucleus and stimulate the 
transcription of specific target genes. It has been described that NF-κB regulates more of 
than 150 genes, including those involved in immunity and inflammation, anti-apoptosis, 
cell proliferation and the negative feedback of the NF-κB signal (11). A partial list of 
genes relevant to the inflammatory response whose expression is stimulated by NF-κB 
activation is shown in Table 1.  
 In turn, IKKα activates the NF-κB non-canonical pathway by phosphorylating 
precursor p100, followed by its polyubiquitination by SCFβTrCP and further proteasomal-
processing to mature p52. TRAF family members and NF-κB-inducing kinase (NIK) also 
play an essential role in the non-canonical pathway.  Indeed, NIK phosphorylates 
IKKα. This process is generally slower than the canonical pathway and leads to a delayed 
activation of p52-containing complexes, such as p52/RelB. The activation of the non-
canonical pathway is restricted to certain TNF receptor (TNFR) superfamily members 
such as lymphotoxin β receptor (LTβR), B-cell activating factor (BAFF), CD40 ligand, 
CD27, CD30 or Receptor Activator of Nuclear Factor-κB (RANK). These molecules are 
involved in lymphoid organ formation, in B cell development, survival and homeostasis, 
and in osteoclastogenesis. Furthermore, the non canonical pathway is also activated by 
the oncogenic viruses EBV and HTLV1 (8,10,16).  
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 A sequential activation of both canonical and non-canonical NF-κB pathways 
generated by few inducers has been described. Thus, an initial activation of the canonical 
pathway is followed by the activation of the non-canonical NF-κB pathway. Therefore, 
the orchestrated expression of their specific and/or common NF-κB target genes, in a 
cell-type and stimulus-type specific fashion, contributes to the pleiotropic biological 
functions of this ubiquitous transcription factor (16).  
  
Role of the NF-κB in inflammatory arthritis 
 Although NF-κB plays an essential beneficial role in normal physiology, 
inapropiate regulation of NF-κB activity has been implicated in the pathogenesis of 
several inflammatory diseases including rheumatic diseases such as rheumatoid arthritis 
(RA), osteoarthritis (OA), spondyloarthropaties (SpA), systemic lupus erithematosus 
(SLE), crystal induced-arthropaties, etc. (17) (Table 2).   
 It has been shown that NF-κB is involved in the differentiation and activation of 
immune cells including macrophages; dendrytic cells (DCs), granulocytes, as well as 
osteoclasts and chondrocytes (18). Thus, differentiation of monocyte precursors to 
macrophages requires NF-κB-dependent transcription of anti-apoptotic genes. Mature 
macrophage expression of the canonical NF-κB pathway is very important for 
establishing innate and adaptive immunity through its microbial activation via Toll-like 
receptors (TLRs), antigen-processing/presentation and lymphocytes co-stimulation (19). 
The development of DCs is mainly enhanced by RelB and its presence is required for 
antigen processing and presentation in these cells, however, impairment of the canonical 
NF-κB pathway also inhibited DCs maturation.and survival (20,21). During granulocyte 
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differentiation, the canonical NF-κB pathway is activated in the setting of orchestrated 
chemokines/cytokines interaction (22). Mature normal granulocytes express NF-κB-
dependent anti-apoptotic genes and lack p52 and RelB (18,23). Intact, both canonical and 
non-canonical NF-κB signaling pathways are also crucial for T and B cell differentiation 
and homeostasis (18,24). The development of lymphoid tissues, particularly lymph nodes 
and Peyer’s patches, is influenced by both canonical and non-canonical NF-κB pathways, 
however the non-canonical pathway related to LTβR is particularly relevant in these 
processes (25,26). The beneficial and harmful roles of NF-κB are diagrammatically 
shown in Figure 1.   
 
NF-κB in rheumatoid arthritis.  There is a very important NF-κB activation in 
synovial tissue from patients with RA.  Indeed, NF-κB activation is significantly higher 
in RA than in OA, although p50 and p65 NF-κB are abundant in both rheumatoid and 
osteoarthritic synovium (27).  RA and SpA synovial tissues show that the numbers of 
cells expressing NF-κB1 at the cartilage-pannus junction is significantly higher than in 
other areas; a similar finding was observed in the number of cells expressing RelA in RA 
synovium, but no in SpA synovium. Furthermore, the numbers of NF-κB1+ and RelA+ 
cells in OA synovium were similar to those observed at the non-cartilage-pannus junction 
sites in all inflammatory tissues studied (28). In patients with RA and OA, 
immunoreactive IKK is abundant in primary fibroblast-like synoviocytes (FLS) and both 
IKKα and IKKβ are constitutively expressed at the mRNA level. Following TNF-α and 
IL-1 stimulation of RA FLS, IKKβ activation is a key event for NF-κB mediated 
induction of IL-6, IL-8, ICAM-1 and collagenase gene expression (29).  
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Animal models of inflammatory arthritis also support the concept that NF-κB plays 
a very active role in the development and progression of arthritis in vivo. NF-κB 
activation prior to the onset of clinical manifestations of arthritis has been found in both, 
murine type II collagen-induced arthritis (CIA) and rat adjuvant induced arthritis (AIA). 
In the first model, NF-κB expression correlated better than AP-1 expression with 
collagenase-3 (MMP-13) and stromelysin (MMP-3) levels, however, both transcription 
factors were activated before onset of clinical arthritis and metalloproteinase gene 
expression (30). Also, a shift to nuclear NF-κB localization was shown in chondrocytes 
during cartilage destruction in the early stage of arthritis in DBA/1 mice immunized with 
type II collagen (31).  In the second model, expression of activated NF-κB p65 was found 
in the synovial lining layer and surrounding the blood vessels in the inflamed synovium, 
being stronger in the injected hindpaw than that in the noninjected one (32). In addition, 
intraarticular gene transfer of IKKβ caused arthritis in normal rats, characterized by 
severe paw swelling, inflammatory histologic changes, increased IKK activity and 
enhanced NF-κB DNA binding activity. Thus, these experiments confirm that 
IKKβ activation is a crucial event in the initiation of synovitis (33).      
 NF-κB family members play also a pivotal role in osteclastogenesis and 
inflammation-induced bone loss observed in RA. The OPG/RANK/RANKL triad is 
particularly relevant to bone homeostasis. Thus, osteoclasts express RANK and 
osteoblasts express RANKL and its soluble decoy receptor osteoprotegerin (OPG) that 
blocks RANK binding to its ligand RANKL (34). Furthermore, mice deficient for RANK 
or RANKL show lack of precursor cells differentiation to osteoclast, leading to 
osteopetrosis (35,36). The p50/p52 doble knock-out mice has shown similar osteopetrotic 
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phenotype (37). In addition, recent experiments in mice have demostrated that IKKβ 
activation is indispensable in the signal transduction from RANK to NF-κB. Absolute 
ausence of IKKβ activity, and not of IKKα activity, leads to lack of osteoclastogenesis 
and bone unresponsiveness of IKKβ-deficient mice to inflammation (38). Therefore, the 
canonical NF-β pathway is crucial for osteoclastogenesis in vivo and its specific 
inhibition represents a logical alternative strategy to the current therapies. In contrast, the 
role of the non-canonical NF-β pathway is less evident in vivo; nevertheless, it has been 
recently shown to be crucial for the antigen-mediated periarticular bone erosion that 
accompanies inflammatory arthritis in several murine models (39,40). 
 
 NF-κB in juvenile rheumatoid arthritis. Since juvenile rheumatoid arthritis 
(JRA) shares many pathogenetic mechanisms with other autoimmune diseases, the 
activation of NF-κB is also thought to play a relevant role in its molecular 
physiopathology. Thus, NF-κB p65 nuclear expression and activation have been detected 
in the synovial tissue and fluid cells from polyarticular JRA and RA patients (41). Also, 
increased mRNA and protein expression of RANK and RANKL have been found in 
synovial dendritic cells of the joints from children with oligoarticular and polyarticular 
JRA. RANK/RANKL interactions may contribute to the survival of inflammatory 
articular cells, as well as to erosions and osteoporosis in JRA (42). 
 
 NF-κB in spondyloarthropathies. Few studies have directly addressed the role of 
NF-κB activation in SpA. Initially, NF-κB activation was found to be exclusively 
mediated by p50/p50 homodimers in synovial T cells from patients with reactive arthritis 
(ReA) and ankylosing spondylitis (AS), in contrast with the predominance of p50/65 
   
   
 
12 
heterodimers in rheumatoid synovial T cells (43). Recently, another study found that p65 
DNA-binding was decreased during the course of infliximab therapy whereas p50 DNA-
binding remained elevated in lymphocytes from AS patients (44). The differential 
activation of NF-κB subunits p50 and p65 might provide insights into the NF-κB role in 
the pathogenesis of Spa and in the effects of anti-TNF-α therapy in AS.  
 In addition, the involvement of NF-κB activation in psoriatic arthritis (PsA) has 
recently been studied with growing interest. Indeed, cells expressing active NF-κB p65 
were primarily localized to lining layer and perivascular macrophages in PsA synovial 
membrane. Expression of NF-κB p65 was equal in lining layer from both PsA and RA 
patients, but lower in PsA than RA sublining. However, the histologic findings did not 
correlate with clinical parameters of disease (45). In a further study, phosphorylated IκBα 
expression and histological severity scores significantly decreased following six months 
of etanercept treatment in PsA synovium (46).  
 
 NF-κB in crystal induced arthropathies. NF-κB activation has been described 
in the response of articular cells to monosodium urate (MSU), calcium pyrophosphate 
dihydrate (CPPD) and basic calcium phosphate (BCP) crystals. Indeed, transcriptional 
activation of important inflammatory mediators such as IL-8, chemokines and iNOs by 
NF-κB and AP-1, as well as ERK 1/2 signaling are essential for the mononuclear 
phagocyte response to CPPD and MSU crystals (47-49). NF-κB and AP-1 have also been 
shown to mediate the effects of the BCP crystals in human fibroblasts (50). 
 
 NF-κB in septic arthritis. NF-κB activity has been studied in some studies of 
septic arthritis. Surprisingly, the clinical course of septic arthritis was not ameliorated in a 
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murine model of S. aureus-induced arthritis systemically treated with antisense 
oligonucleotides (ODN) to p65 NF-κB, alone or in combination with antibiotics. 
However, the bacterial burden in the kidneys and IL-6 levels were significantly increased. 
These findings suggested that p65 antisense therapy approach may not be suitable for 
treatment of septic arthritis because it leads to increased bacterial burden overpassing the 
potential anti-inflammatory benefit of these compounds (51). In contrast, several studies 
suggest a beneficial effect of NF-κB inhibition in other septic conditions. Indeed, 
parthenolide (PAR), an NF-κB inhibitor found in medicinal herbs, blocked LPS-induced 
osteolysis in the mouse calvarium model. NF-κB-dependent osteoclastogenesis and 
osteoclastic bone resorption were inhibited by PAR. Enhanced apoptosis of osteoclasts 
and their precursor cells was observed as well in a dose-dependent manner in this 
bacteria-induced bone destruction model (52).  
 
 NF-κB in systemic lupus erythematosus: NF-κB activation in SLE has been 
shown in in vitro and in vivo studies. SLE T cells have shown decreased expression of 
p65-Rel A heterodimer expression associated with a low level of IL-2 promoter activity 
and altered c-Rel expression and nuclear import (53-55). Moreover, SLE T cells 
increased IL-2 promoter activity to normal levels following transfection with cDNA 
encoding the NF-κB p65 subunit (54). A recent study has been carried out in a mouse 
model that overproduces BAFF, developing a SLE-like disease. BAFF enhanced long-
term B cell survival primarily through the non-canonical NF-κB pathway, while it 
promoted immunoglobulin class switching and generation of pathogenic antibodies 
through the classical pathway. These findings demonstrate that both NF-κB signaling 
pathways are important for development of lupus-like disease associated with BAFF 
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overproduction (56). Remarkably, another study has shown that administration of DCB-
3503, a NF-κB inhibitor, for 10 weeks nearly abrogated inflammatory skin disease with 
little effect on histologic kidney disease in MRL/Fas(lpr) mice (57). 
 
 NF-κB in osteoarthritis. NF-κB signaling pathways mediate critical events in the 
inflammatory response by chondrocytes, leading to progressive extracellular matrix 
damage and cartilage destruction (17,58). Numerous studies have examined the effects of 
NF-κB on chondrocyte functions. The NF-κB and the MEK1/2 kinase pathways were 
found to mediate inhibition of type II collagen and link protein gene expression by TNF-
α as well as upregulation of MMP-1, MMP-3 and MMP-13 RNA/protein expression 
induced by TNF-α or IL-1β in articular chondrocytes (59-61). NF-κB has also been 
shown to mediate fibronectin fragment induced-chondrocyte activation and increased 
expression of IL-6, IL-8, MCP-1, growth-related oncogenes and MMP-13 by human 
articular chondrocytes (62,63). Furthermore, NF-κB production was increased with donor 
age in IL-1β stimulated human articular chondrocytes (63). Finally, a study performed in 
bovine chondrocytes showed that DNA binding of NF-κB and AP-1 was significantly 
higher in hypoxic and reoxygenated chondrocytes treated with IL-1β than in normoxic 
chondrocytes (64). 
 It is also known that NF-κB signal pathways are employed by mechanical signals 
for transcriptional regulation of proinflammatory genes that are involved in catabolic 
events in chondrocytes. Mechanical strains of low magnitude prevent nuclear 
translocation of NF-κB, resulting in inhibition of proinflammatory gene expression. In 
contrast, mechanical strains of high magnitude induce this translocation, and thus cause 
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proinflammatory gene induction.  Furthermore, mechanical overload induces similar 
intracellular events to those generated by proinflammatory cytokines in arthritis (65,66).  
 Besides its anti-inflammatory effects, it has been suggested that NF-κB may also 
play a role in chondrocyte apoptosis. Under certain conditions NF-κB exerts prosurvival 
effects in articular cartilage. Thus, in human chondrocytes NF-κB activation partially 
mediates the anti-apoptotic effects of IL-1β against death receptor CD-95 (FAS/APO-1) 
(67).  In contrast, other studies have described NF-κB involvement in apoptotic events in 
articular chondrocytes. For example, it has been shown that NF-κB activation mediates 
the apoptotic effect of NO in articular chondrocytes (17,68,69). 
 
Inhibition of NF-κB by pharmacologic agents 
 An increasing number of NF-κB inhibitors, including several clinically important 
anti-inflammatory drugs, have been reported (70) as illustrated in Figure 2. 
Glucocorticoids are potent inhibitors of the NF-κB pathway through several mechanisms 
(71).  Glucocorticoids induce the transcription of the IκBα gene through the glucorticoid 
receptor (GR), causing an increased cytosolic retention of NF-κB (72,73).  Glucorticoids 
may also inhibit the NF-κB DNA binding activity through direct interaction between GR 
and components of the NF-κB binding sites in various gene promoters (74). The activated 
GR can also interact with NF-κB by direct protein-protein binding, preventing the 
activation of the NF-κB pathway in certain types of cells (75). Lastly, competition can 
occur between GR and NF-κB, limiting amounts of the coactivators CREB-binding 
protein (CBP), CBP-associated factor (p/CAF) and steroid receptor coactivator-1(SRC-1) 
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(76). Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, salycilate, 
ibuprofen, indomethacin, diclofenac, and sulindac inhibit IKKβ activity, preventing IκBα 
phosphorylation, consequently blocking the activation of the NF-κB pathway (77,78). It 
has also been shown that sulfasalazine suppresses IκB phosphorylation, probably owing 
to the effects of its anti-inflammatory metabolite, 5-aminosalicylic acid (79). 
 The immunosuppresive agents cyclosporin A and tacrolimus (FK-506) also 
inhibit the NF-κB pathway. Cyclosporin A inhibits the protease activity of the 20S 
proteasome complex preventing IκBα degradation in murine macrophages, Jurkat 
lymphoma cells, and in mouse and human T lymphocytes (80). FK506 blocks 
translocation of c-Rel from the cytoplasm to the nucleus in both B and T cells, and Jurkat 
cells, leading to a decreased expression of IL-2 and its receptor (81). Several other agents 
have also been described to inhibit NF-κB including vitamin C, vitamin E, curcumin, 
flavonoids, lactacystin, thalidomide, leflunomide, pyrrolidine dithiocarbamate, 
glucosamine, diacehrein and resveratrol (17). 
 In addition, since the nonclassical anti-inflammatory activity of estrogen has 
been attributed to interference with NF-κB signaling by multiple mechanisms, agents that 
target estrogen receptors (ER) and show selective inhibition of NF-κB activity have been 
synthesized recently. Thus, WAY-169916, a small molecule ER ligand that inhibits NF-
κB transcriptional activity but is devoid of conventional estrogenic activity, has 
demonstrated benefitial effects in two models of inflammatory disease: the HLA-B27 
transgenic rat model of inflammatory bowel disease (IBD) and the Lewis rat AIA model. 
In both models, a near complete reversal in hindpaw scores was observed as well as 
marked improvement in the histological scores. In the Lewis rat AIA model, WAY-
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169916 also markedly suppressed induction of serum acute phase proteins. Furthermore, 
WAY-169916 also suppressed TNF-α-mediated inflammatory gene expression in FLS 
from RA patients. Therefore, this class of compounds might have a potential utility in the 
treatment of inflammatory arthritis (82,83).   
 
 Novel therapeutic strategies aimed at the specific inhibition of key elements in the 
NF-κB pathway activation are being developed, causing great expectation regarding their 
potential effects as arthritis treatments (84-87). For example, proteasome function 
inhibitors, decoy oligonucleotides, and peptides that inhibit nuclear localization of NF-κB 
have been utilized to inhibit NF-κB signaling in animal models (88,89). Daily oral 
treatment with PS-341 (bortezomib), a proteasome inhibitor recently approved by the 
FDA for the treatment of multiple myeloma, decreases significantly NF-κB activity in 
rats with streptococcal cell wall-induced polyarthritis. This decrease is associated with 
lower serum levels of IL-1, IL-6 and NO metabolites (90). Decoy oligodeoxynucleotides 
(ODN), short double stranded DNA containing the consensus binding sequence of NF-κB 
were introduced by intraarticular injection into the hind joints of CIA rats. In these 
experiments, NF-κB decoy ODN decreased the severity of hind-paw swelling, suppressed 
IL-1 and TNF-α in the arthritic synovium, and abrogated joint destruction as evidenced 
by histologic and radiographic studies (91). In a similar approach, the same investigators 
injected NF-κB decoy ODN into the knee joints of anterior cruciate ligament transaction 
(ACLT) OA model rats.  Histopathological findings from knee joints injected with the 
naked NF-κB decoy ODN showed a statistically significant amelioration as assessed by 
the Mankin 95 criteria, compared with either a scrambled decoy ODN or physiological 
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buffer administration. Also, naked NF-κB decoy ODN significantly inhibited the levels 
of IL-1β or TNF-α in the synovium and the cartilage, compared with the scrambled 
decoy ODN (92). Small peptides called protein transduction domains (PDTs) and cell 
penetrating peptides (CPPs) able to transport much larger molecules such as 
oligonucleotides, peptides, full-length proteins, bacteriophages, etc. across cellular 
membranes of almost all tissues have also been employed, modifying cellular function in 
the absence of ectopic gene expression (93). One example is BMS-205820, another novel 
selective NF-κB inhibitor. It contains a synthetic PTD carrying two nuclear localization 
sequences (NLS) capable of blocking NF-κB nuclear localization. This inhibition 
resulted in a decrease of cell surface protein expression, cytokine production, and T cell 
proliferation, and showed efficacy in a mouse septic shock model as well as in an IBD 
mouse model (94).  
 IKKβ has become a particularly appealing target for therapeutic intervention in 
RA and OA because of its crucial role in NF-κB pathway activation. Administration of 
IKKβ resulted in a potent increase of cytokine production in numerous cell types 
including synoviocytes and chondrocytes. Thus, in AIA rats, intraarticular gene therapy 
delivering a dominant-negative IKKβ (ΙΚΚβ dn)−adenovirus construct inhibits NF-κB 
translocation; consequently, cytokine-induced IL-6, IL-8 and ICAM-1 expressions are 
suppressed (28). In the same experimental model, recombinant adeno-associated virus 5 
(rAAV5) carrying IKKβ injected intraarticularly, significantly reduced paw swelling, IL-
6 and TNF-α levels in early arthritis. No significant effect was found on cartilage and 
bone destruction, however.  Remarkably, this genetic construct also reduced IL-6 
production following TNF-α stimulation in whole human RA synovial tissue biopsies ex 
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vivo, representing a promising step in the development of gene therapy for human 
arthritis (95).  
Gene constructs that overexpress IκB or express an engineered protein without 
the sites for phosphorylation (IkB super repressor) have also been used. However, there 
have been technical difficulties for their appropriate intracellular delivery, therefore, viral 
or non-viral vectors are necessary to carry them into the cell. A chimeric molecule that 
contains the super-repressor IκBα (srIκB) fused to the human immunodeficiency virus 
Tat protein PTD (Tat-srIκBα) has been examined in a rat model of pleuresy. This 
chimeric molecule showed a good effect, causing reduced cellular infiltration as well as 
increased apoptosis of leukocytes in the sites of inflammation and decreased levels of the 
proinflammatory cytokines TNF-α and IL-1β in the exudates (96). Recently, a peptide 
corresponding to the NEMO-binding domain (NBD) of IKKβ linked to Drosophila 
Antennapedia protein (Antp) has been shown to inhibit NF-κB signaling in animal 
models and rheumatoid tissue cultures. Intra-articular injection of the NBD peptide in the 
rat AIA model, reduced severity of arthritis, radiological damage, synovial cellularity and 
TNF-α and IL-1-β expression. NBD is able to block the interaction of IKKα and IKKβ 
with the regulatory subunit IKKγ (NEMO). Because of its highly defined site of action, 
NBD inhibits only activated but not basal levels of NF-κB and is unlikely to affect other 
essential kinases, in contrast to other small-molecule NF-κB inhibitors (97). Also, 
adenovirus transferring IκBα into late stage OA synovial cells were shown to regulate the 
spontaneous expression of an array of proinflammatory cytokines, chemokines and 
MMPs. Thus, the gene therapy delivered to synovial cells could be a potential option for 
OA treatment (98,99).   
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Also, new studies with small molecule inhibitors have further strengthened the 
role of IKKβ. One of these small molecules, sc-514 inhibits IκB 
phosphorylation/degradation and p65 NF-κB phosphorylation/transactivation induced by 
IL-1 in RA synovial fibroblasts in a dose-dependent manner (100). Another IKKβ 
inhibitor, BMS-345541, was administered to treat murine CIA in both prophylactic and 
therapeutic dosing regimens. Prophylactic BMS-345541 showed a dose-dependent 
efficacy reducing the incidence of arthritis, clinical disease severity and IL-1β mRNA 
levels and blocking inflammation and joint destruction evaluated histologically. 
Therapeutic BMS-345541 reduced clinical and histological end points in animals with 
preestablished disease, showing a dose-dependent effect. Furthermore, use of high doses 
resulted in clinical remission of the disease (101).  ML120B, a novel IKKβ inhibitor, 
inhibited paw swelling in a dose-dependent manner and offered significant protection 
against cartilage and bone erosion in the AIA rat model. Using novel in vivo imaging 
techniques, the association between the inhibition of NF-κB activity and the dampening 
of chronic inflammatory processes was documented in arthritic joints (102,103). 
 Dehydroxymethylepoxyquinomicin (DHMEQ), a novel small selective inhibitor 
of NF-κB translocation, decreased the severity of clinical arthritis and improved 
radiographic and histopathologic scores in murine CIA, as well as suppressed 
proinflammatory cytokines expression and cell proliferation in RA FLSs.  Interestingly, 
in further experiments performed in the animal model, DHMEQ significantly suppressed 
osteoaclastogenesis and NFATc1 expression along the inner surfaces of bone lacunae and 
the eroded bone surface in arthritic joints.  Serum levels of RANKL, OPG and M-CSF 
were not affected by the treatment. However, DHMEQ neither suppressed spontaneous 
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expression of RANKL nor M-CSF in culture of RA FLSs. Thus, DHMEQ may suppress 
RA associated-osteoclastogenesis, through NFATc1 downregulation (104,105). In an 
interesting cellular therapy approach, attempting to influence the antigen-specific 
immune response rather than to produce a broad antiinflammatory effect, dendritic cells 
(DCs) treated with the NF-κB inhibitor BAY 11-7082 were injected intraarticularly into 
methylated bovine serum albumin (mBSA) induced-arthritic joints of C57BL/6 mice. 
DCs exposed to mBSA and further treated with BAY 11-7082 suppressed inflammation 
and erosion, showing potential as antigen-specific therapy for autoimmune inflammatory 
arthritis (106). 
 Other new promising therapeutic strategies to target specific proteins of the NF-
κB pathway include improved antisense therapy and RNA interference. Locked Nucleic 
Acid-Antisense (LNA), morpholino oligonucleotides, and particularly, RNA interference 
have been developed in recent years (107-110).  RNA interference, a general post-
transcriptional gene silencing mechanism, is initiated by a double stranded RNA which 
after being introduced into cells is cleaved into 21 or 22nt dsRNA fragments. These 
fragments called small interfering RNA (siRNA) induce the formation of a 
ribonucleoprotein complex (RNAi silencing complex) that mediates sequence-specific 
cleavage of the targeted transcript mRNA by the antisense RNA strand, thus promoting 
mRNA degradation of a specific mRNA (109,110). Indeed, siRNA targeting of NF-κB 
p65 subunit has shown promising results, decreasing significantly the expression of 
COX-2, iNOS and MMP-9 mRNA/protein levels in rat chondrocytes stimulated with IL-
1β and TNF-α (111). Furthermore, in a recent in vivo study, an adenoviral vector carrying 
a siRNA targeting NF-κB p65 subunit inhibited early changes in an OA rat model. IL-1β 
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and TNF-α synovial fluid levels, cartilage degradation and synovial inflammation were 
all reduced in the early stages of this experimental OA model (112). 
 
Conclusions 
The NF-κB family of transcription factors plays a crucial role in the distinctive 
inflammatory processes characteristic of certain rheumatic diseases leading to bone and 
cartilage destruction, and articular damage. Therefore, NF-κB inhibition is a rational 
objective in the treatment of rheumatic diseases. NSAIDs, glucorticoids, nutraceuticals, 
natural products and certain disease-modifying anti-rheumatic drugs (DMARDs) have 
been described to decrease NF-κB activation. Yet, novel therapeutic strategies targeting 
key elements in the NF-κB  pathway including IKK, 26S proteasome, p65 and p50 
subunits have been and continue to be developed, and small molecule inhibitors, chimeric 
molecules, improved antisense therapy and RNA interference are part of the new 
approaches to block the NF-κB pathways.  
 Thus, NF-κB transcription factors appear as a very attractive target for treatment 
of arthritis; however, some concerns about the systemic and indiscriminate blockade of 
its numerous beneficial effects, as well as technical problems for local delivery of a 
potential agent through gene therapy still remain. Further in vivo studies will increase our 
understanding of the true significance of NF-κB inhibition and provide the foundations 
for the development of effective therapy for various joint diseases.  
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• GENES THAT ENCODE MOLECULES INVOLVED IN IMMUNITY:  
     Cytokines:  TNF-α, IL-1β, IL-2, IL-6, IL-8, IL-12, INF-γ, GM-CSF 
     Adhesion molecules:  e-selectin, ICAM-1, VCAM-1 
     Chemokines:  CXCL1, ENA-78, eotaxin, IL-8, MIP-1α, MCP-1, RANTES 
     Receptors:  CD-3g, CD-40, CD-48, CD68, MHC-I, TLR-2 
     Inducible enzymes:  COX-2, iNOS 
         
• GENES THAT ENCODE MOLECULES INVOLVED IN CELL   
   PROLIFERATION, APOPTOSIS AND CELL CYCLE: 
     Anti-apoptosis:  AF-1/BF-1, c-IAP-1, c-IAP-2, c-FLIP, Bcl-2,  
      TRAF-1, TRAF-2 
     Apoptosis:  Bax, caspase 11, Fas, FasL 
     Proliferation:  c-myc, cyclin D1, ephrin A1, E2F3a 
 
.  GENES THAT ENCODE MOLECULES INVOLVED IN TISSUE  
   DAMAGE:  
         Extracellular matrix degradation: catephsyn B, cathepsyn K, MMP-
1,  
      MMP-3, MMP-13 
• GENES THAT ENCODE MOLECULES INVOLVED IN NEGATIVE   
   FEEDBACK OF NF-κB:   
     IκBα, IκBβ, A20 
    
Partial list of NF-κB-induced genes 
Table 1 
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• Rheumatoid arthritis    
• Juvenile rheumatoid arthritis             
• Osteoarthritis  
• Systemic lupus erythematosus 
• Spondyloarthropaties  
• Crystal induced arthropaties 
• Septic arthritis 
Rheumatic Disorders associated with NF-κB activation 
Table 2 
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FIGURE LEGENDS 
 
Fig 1. Beneficial and harmful role of NF-κB in inflammatory arthritis. 
 
Fig 2. NF-κB signaling pathways. Many current therapeutic agents and future strategies 
block the canonical NF-κB pathway at different steps: 1) I-κB phosphorylation: 
NSAIDs (aspirin, salicylate, ibuprofen, sulindac), 5-ASA, IKKβ inhibitors, NBD peptide. 
2) Protease activity of the 26 S proteasome complex: Bortezomib*, Cyclosporin A, sc-
514, lactacystin. 3) Reduction of levels of NF-κB subunits p65, p50, c-Rel and others: 
siRNA. 4) Nuclear translocation of NF-κB subunits p65, p50, c-Rel and others: FK-
506, BMS-205820, I-κB super repressor, Tat-srIκBα, DHMEQ*. 5) NF-κB DNA 
binding: Glucocorticoids, NF-κB ODN, NF-κB morpholinos. *Some therapeutics agents 
also block the non-canonical pathway NF-κB pathway.  
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Fig 2 
 
